FDA Approval Targets Rare Kidney Disease - Summary - MDSpire

FDA Approval Targets Rare Kidney Disease

Phase 3 data showed greater proteinuria reduction vs irbesartan, with similar tolerability and a 1.1 mL/min/1.73 m² difference in estimated glomerular filtration rate at 108 weeks.

  • By

  • Kathryn Wighton

  • April 14, 2026

  • 2 min

Share

Objective:

To report on the FDA approval of FILSPARI (sparsentan) for treating focal segmental glomerulosclerosis without nephrotic syndrome.

Key Findings:
  • Sparsentan reduced proteinuria by 46% compared to 30% with irbesartan at 108 weeks.
  • In patients without nephrotic syndrome, proteinuria reductions were 48% with sparsentan vs 27% with irbesartan.
  • Mean estimated glomerular filtration rate decline was similar between sparsentan and irbesartan.
Interpretation:

Sparsentan represents a significant advancement in the pharmacologic treatment of focal segmental glomerulosclerosis, targeting key pathways involved in kidney injury.

Limitations:
  • Sparsentan is available through a restricted risk evaluation and mitigation strategy due to hepatotoxicity risk.
  • Liver function must be monitored, and the drug is contraindicated in pregnancy.
Conclusion:

Sparsentan is the first approved treatment for focal segmental glomerulosclerosis without nephrotic syndrome, with promising efficacy and tolerability.

Original Source(s)

FDA Approval Targets Rare Kidney Disease

  • by Kathryn Wighton

  • April 14, 2026

Related Content

Evaluation of a pharmacist-led digital hypertension management program in a tertiary hospital in Singapore

Top 10 States with the Lowest Costs for Running a Medical Practice

These 10 states posted some of the lowest 2026 Medicare practice expense GPCI among states that CMS treats as a single statewide locality, with broader price levels and selected malpractice or tax indicators adding context.

Top 10 Evidence-Based Essentials in Internal Medicine

A structured framework of guidelines, trials, therapies, and tools used in clinical practice.